Stifel Reiterates Buy on Treace Medical Concepts, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Rick Wise has reiterated a 'Buy' rating on Treace Medical Concepts (NASDAQ:TMCI) and maintained a price target of $28.
October 02, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst maintains a 'Buy' rating on Treace Medical Concepts with a $28 price target.
The reiteration of a 'Buy' rating by a Stifel analyst and the maintenance of a $28 price target indicates a positive outlook for TMCI. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100